Daiichi Sankyo’s pexidartinib has become the first FDA-approved therapy for tenosynovial giant cell tumour (TGCT), a rare form of tumour affecting joints and tendons. TGCT – which is also ...
The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...
AstraZeneca and Daiichi Sankyo withdrew an application in the European Union for the drug to treat a type of lung cancer in December following feedback from regulatory advisers. Mixed results from ...
Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on January 19 and set a price ...
Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...
A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback